Evaluation of experimental animal behaviors through establishment of an ovalbumin-induced experimental mouse model of allergic rhinitis

Yu-Hsing Lin, Yun-Xuan Chang, Ying-Ching Hung, Tzu-Yun Chi, Ping-Min Huang, Ya-Peng Wang, Tsung-Han Wu, Yen-Jung Lu, Chia-Yu Lin, Guan-Hong Chen, Chien-Chao Chiu, Ching-Feng Chiu, Hsuan-Wen Chiu, Wei-Huang Tsai, Chia-Chi Chen, Shao-Wen Hung
{"title":"Evaluation of experimental animal behaviors through establishment of an ovalbumin-induced experimental mouse model of allergic rhinitis","authors":"Yu-Hsing Lin, Yun-Xuan Chang, Ying-Ching Hung, Tzu-Yun Chi, Ping-Min Huang, Ya-Peng Wang, Tsung-Han Wu, Yen-Jung Lu, Chia-Yu Lin, Guan-Hong Chen, Chien-Chao Chiu, Ching-Feng Chiu, Hsuan-Wen Chiu, Wei-Huang Tsai, Chia-Chi Chen, Shao-Wen Hung","doi":"10.53430/ijbpru.2022.2.1.0030","DOIUrl":null,"url":null,"abstract":"Allergic rhinitis (AR) was also called hay fever which was a type of nasal inflammation when the immune system overreacts to environmental allergen exposures. AR’s clinical symptoms included a runny or stuffy nose, sneezing, red, itchy, watery eyes, and eye swelling. The fluid in the nasal cavity was usually clear. Patients with AR can affect sleep and work qualities. Seriously, the AR symptoms can also cause asthma, allergic conjunctivitis, or atopic dermatitis. Therefore, it is an important issue to attenuate AR symptoms and research the novel therapeutic drugs for AR patients. The purpose of this study was to introduce an easy-to-establish experimental mouse model of AR. In this study, the male BALB/c mice were divided respectively into as the Group A (n = 12) and the Group B (n = 12). Group A and Group B were designed as the normal control and RA, respectively. BALB/c mice in Group B were sensitized by intraperitoneal injection of ovalbumin (OVA) on day 0, day 4, day 13, and day 20, followed by continuous nasal administration of OVA solution once per day between day 21-43. BALB/c mice in Group A received sensitization of intraperitoneal injection of phosphate-buffered saline (PBS) on day 0, day 4, day 13, and day 20 and continuous nasal administration of PBS instead of OVA once per day between day 21-43. Before and after sensitization, the frequencies of nasal symptoms (sneezing, nasal rubbing) were recorded and counted. Results were showed that sneezing times in Group B were higher than Group A on D29, D30, D36, and D43 of the experiment. The sneezing times in Group A were significant higher on D29 and D30 of the experiment. However, the sneezing times in Group B were significant higher on D29, D30, D36, and D43 of the experiment. The rubbing times in Group B were higher than Group A on D29, D30, D36, and D43 of the experiment. The rubbing times in Group A were significant higher on D30 and D43 of the experiment. However, the rubbing times in Group B were significant higher on D29, D30, D36, and D43 of the experiment. Based on these results, a successful mouse model of AR has been established. We hope that this RA mouse model will provide a tool for the research of the novel AR therapeutic drugs and apply these novel AR therapeutic drugs to attenuate the AR symptoms in AR patients in the future.","PeriodicalId":393912,"journal":{"name":"International Journal of Biology and Pharmacy Research Updates","volume":"277 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biology and Pharmacy Research Updates","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53430/ijbpru.2022.2.1.0030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Allergic rhinitis (AR) was also called hay fever which was a type of nasal inflammation when the immune system overreacts to environmental allergen exposures. AR’s clinical symptoms included a runny or stuffy nose, sneezing, red, itchy, watery eyes, and eye swelling. The fluid in the nasal cavity was usually clear. Patients with AR can affect sleep and work qualities. Seriously, the AR symptoms can also cause asthma, allergic conjunctivitis, or atopic dermatitis. Therefore, it is an important issue to attenuate AR symptoms and research the novel therapeutic drugs for AR patients. The purpose of this study was to introduce an easy-to-establish experimental mouse model of AR. In this study, the male BALB/c mice were divided respectively into as the Group A (n = 12) and the Group B (n = 12). Group A and Group B were designed as the normal control and RA, respectively. BALB/c mice in Group B were sensitized by intraperitoneal injection of ovalbumin (OVA) on day 0, day 4, day 13, and day 20, followed by continuous nasal administration of OVA solution once per day between day 21-43. BALB/c mice in Group A received sensitization of intraperitoneal injection of phosphate-buffered saline (PBS) on day 0, day 4, day 13, and day 20 and continuous nasal administration of PBS instead of OVA once per day between day 21-43. Before and after sensitization, the frequencies of nasal symptoms (sneezing, nasal rubbing) were recorded and counted. Results were showed that sneezing times in Group B were higher than Group A on D29, D30, D36, and D43 of the experiment. The sneezing times in Group A were significant higher on D29 and D30 of the experiment. However, the sneezing times in Group B were significant higher on D29, D30, D36, and D43 of the experiment. The rubbing times in Group B were higher than Group A on D29, D30, D36, and D43 of the experiment. The rubbing times in Group A were significant higher on D30 and D43 of the experiment. However, the rubbing times in Group B were significant higher on D29, D30, D36, and D43 of the experiment. Based on these results, a successful mouse model of AR has been established. We hope that this RA mouse model will provide a tool for the research of the novel AR therapeutic drugs and apply these novel AR therapeutic drugs to attenuate the AR symptoms in AR patients in the future.
通过建立卵清蛋白诱导的变应性鼻炎实验小鼠模型评价实验动物行为
过敏性鼻炎(AR)也被称为花粉热,这是一种鼻腔炎症,当免疫系统对环境过敏原暴露过度反应时。AR的临床症状包括流鼻涕或鼻塞、打喷嚏、眼睛发红、发痒、流泪和眼睛肿胀。鼻腔内的液体通常是清澈的。AR患者会影响睡眠和工作质量。严重的是,AR症状还可引起哮喘、过敏性结膜炎或特应性皮炎。因此,减轻AR症状和研究AR患者的新型治疗药物是一个重要的课题。本研究旨在建立一种易于建立的AR小鼠实验模型。本研究将雄性BALB/c小鼠分别分为A组(n = 12)和B组(n = 12)。A组为正常对照组,B组为RA组。B组BALB/c小鼠分别于第0天、第4天、第13天和第20天腹腔注射卵清蛋白(OVA)致敏,然后在第21-43天期间连续每天鼻给卵清蛋白溶液1次。A组BALB/c小鼠在第0天、第4天、第13天和第20天腹腔注射磷酸盐缓冲盐水(PBS)致敏,并在第21-43天期间连续鼻腔给药PBS代替OVA,每天1次。在致敏前后,记录并统计鼻部症状(打喷嚏、揉鼻)的频率。结果显示,在实验的第29天、第30天、第36天、第43天,B组打喷嚏次数高于A组。A组在实验第29、30天打喷嚏次数显著高于对照组。而B组在实验的第29、30、36、43天打喷嚏次数显著增加。实验D29、D30、D36、D43时,B组摩擦次数高于A组。A组在实验第30、43天的摩擦次数显著高于对照组。而B组在实验的D29、D30、D36、D43的摩擦次数显著高于对照组。基于这些结果,成功建立了小鼠AR模型。我们希望该RA小鼠模型能够为新型AR治疗药物的研究提供工具,并在未来应用这些新型AR治疗药物来减轻AR患者的AR症状。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信